Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our Q3 2020 Report: Global Trends in Biopharma applies the latest data to analyze current activities in the life science deal landscape.

This quarter shaped to be another positive one for biopharma IPOs and strategic transactions across the globe. And in the US, the rapid need to raise capital without the lengthy IPO process brought back a financing vehicle to take small companies public – SPACs.

A few highlights:

US

• Private financings saw one of the strongest Q3s on record, and 2019/2020 biopharma IPOs continue to perform well in the public markets, suggesting investors are bullish long-term on new biopharma opportunities

EU

• European biotech financings set a historical record this quarter, demonstrating robust equity markets and increased interest in the region

China

• In the Chinese stock market, the SSE Composite Index has fully recovered and stabilized while the top 16 pharma companies listed in mainland China peaked out in early August

Japan

• Venture financing deals in 2020 continues its record-setting pace in Japan, as it already exceeds all-time high in the volume and value previously set in 2018

We hope you find this latest data that analyzes current activities in the life sciences deal landscape to be helpful.

Please email Geoff Meyerson at ceo@locustwalk.com if you have any questions or if there’s anything in this report you’d like to discuss.